Cargando…
腺癌胸水标本中PD-L1的蛋白表达与临床病理特征及分子改变的相关性研究
BACKGROUND AND OBJECTIVE: Pembrolizumab, an immunotherapy for advanced non-small cell lung cancer (NSCLC), needs to predict treatment response based on test results including immunohistochemistry (IHC), which detects the expression of programmed death ligand 1 (PD-L1). The aim of this study was to e...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118327/ https://www.ncbi.nlm.nih.gov/pubmed/32209183 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.03.03 |